Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Asset disposition
Quarterly results
INOVIO PHARMACEUTICALS, INC. (INO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Quarterly results
08/09/2023 8-K Quarterly results
Docs: "INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update"
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/31/2023 8-K Quarterly results
07/10/2023 SC 13G/A STATE STREET CORP reports a 0.3% stake in EXIT FILING INOVIO PHARMACEUTICALS INC
07/07/2023 SC 13G/A BlackRock Inc. reports a 2.3% stake in INOVIO PHARMACEUTICALS INC
05/18/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/18/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/18/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Inovio Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan",
"Inovio Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan"
05/10/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights"
04/04/2023 EFFECT Form EFFECT - Notice of Effectiveness:
03/31/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/28/2023 ARS Form ARS - Annual Report to Security Holders:
03/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/28/2023 POS EX Form POS EX - Post-effective amendment adding exhibits to registration statement [Rule 462(d)]:
03/01/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
03/01/2023 10-K Annual Report for the period ended December 31, 2022
03/01/2023 POSASR Form POSASR - Post-effective Amendment to an automatic shelf registration statement:
03/01/2023 8-K Quarterly results
Docs: "INOVIO Reports Fourth Quarter and Full Year 2022 Financial Results and Clinical Highlights"
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 6.8% stake in Inovio Pharmaceuticals Inc.
01/31/2023 8-K Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"INOVIO Announces Strategic Reorganization, Continues Efforts to Focus on Promising DNA Medicine Candidates • Cost-saving measures include 11% headcount reduction • Annual savings expected to be approximately $4.3 million • Data readouts expected in first quarter of 2023 for key programs including INO-3107 for RRP and VGX-3100 for cervical HSIL PLYMOUTH MEETING, PA, January 31, 2023 — INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced a strategic reorganization that is intended to deliver on commitments to operational efficiency and better position the company to bring the promise of DNA medicines to patients. The reorganization is expected to..."
11/08/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"INOVIO Reports Financial Results and Highlights for the Third Quarter 2022"
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
08/09/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"INOVIO Reports Financial Results and Highlights for the Second Quarter 2022"
08/09/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/19/2022 8-K Quarterly results
06/30/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/17/2022 8-K Quarterly results
05/11/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/10/2022 8-K Quarterly results
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/11/2022 SC 13G/A STATE STREET CORP reports a 10.5% stake in AMENDED FILING INOVIO PHARMACEUTICALS INC
03/25/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy